Zacks Investment Research on MSN
X4 Pharmaceuticals (XFOR) reports Q4 loss, tops revenue estimates
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $6.01 per share a year ago. These figures ...
The average one-year price target for X4 Pharmaceuticals (NasdaqCM:XFOR) has been revised to $9.52 / share. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results